PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

VJOncology

1 year
431 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).
Up Next Autoplay
New Technology to Streamline Drug Discovery
New Technology to Streamline Drug Discovery
Category: Other
2 Views
Cancer-News 10 hours
Using Technology to Better Understand What Goes Wrong in Cancer
Using Technology to Better Understand What Goes Wrong in Cancer
Category: Breast Cancer
0 Views
Cancer-News 10 hours
How Does This Affect Clinicians Today?
How Does This Affect Clinicians Today?
Category: Breast Cancer
1 Views
Cancer-News 11 hours
Measuring Chromatin Accessibility: How Reliable is This Data?
Measuring Chromatin Accessibility: How Reliable is This Data?
Category: Breast Cancer
0 Views
Cancer-News 11 hours
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
3 Views
Cancer-News 11 hours
Mapping the usual breast development to recognize cancer better
Mapping the usual breast development to recognize cancer better
Category: Breast Cancer
2 Views
Cancer-News 13 hours
Metformin: How Does This Affect Treatment?
Metformin: How Does This Affect Treatment?
Category: Ovarian Cancer
3 Views
Cancer-News 13 hours
New Frontier Possibility for Preventing Ovarian Cancer
New Frontier Possibility for Preventing Ovarian Cancer
Category: Ovarian Cancer
2 Views
Cancer-News 13 hours
"Wild idea" opens possible new boundaries to ovarian cancer prevention
Category: Ovarian Cancer
5 Views
Cancer-News 13 hours
Personalized Algorithms: How is this different?
Personalized Algorithms: How is this different?
Category: Immunotherapy
4 Views
Cancer-News 1 day